GLP-1 Market
LLY $1274.22 ▼ -2.5% NVO $39.03 ▼ -1.0% PFE $30.01 ▼ -1.3% VKTX $24.40 ▼ -5.5% KLRA $12.85 ▼ -3.2% GPCR $21.19 ▼ -3.4% RHHBY $61.17 ▲ +2.6%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Dasatinib

Company
Odense University Hospital
Mechanism
Mechanism not yet reported
Route
Oral
Recruiting trials
29 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

29 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 24, 2026

Find a Clinical Trial Near Me

See recruiting studies for Dasatinib and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT01746836

    Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

    Not yet reported M.D. Anderson Cancer Center 50 participants Est. completion 2030-12-31 1 site
    Other conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    View official trial listing →
  • Recruiting NCT NCT02559778

    Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    Not yet reported Giselle Sholler 500 participants Est. completion 2035-09 28 sites
    Other conditions: Neuroblastoma
    View official trial listing →
  • Recruiting NCT NCT03297606

    Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

    Not yet reported Canadian Cancer Trials Group 720 participants Est. completion 2027-01-31 10 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT03595917

    ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

    Not yet reported Marlise Luskin, MD 40 participants Est. completion 2027-11-01 4 sites Stand-alone
    Other conditions: B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
    View official trial listing →
  • Recruiting NCT NCT03844360

    Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

    Not yet reported Wei Zhao 1500 participants Est. completion 2026-12-31 2 sites Stand-alone
    Other conditions: Hematological Neoplasms
    View official trial listing →
  • Recruiting NCT NCT04603872

    CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

    Not yet reported Zhejiang University 120 participants Est. completion 2026-11-01 1 site Stand-alone
    Other conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphocytic Leukaemia Refractory, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory
    View official trial listing →
  • Recruiting NCT NCT04747912

    Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

    Not yet reported University of Chicago 25 participants Est. completion 2028-03-01 1 site Stand-alone
    Other conditions: Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT04838041

    Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

    Not yet reported Medical College of Wisconsin 51 participants Est. completion 2029-07 5 sites Stand-alone
    Other conditions: Chronic Phase Chronic Myelogenous Leukemia
    View official trial listing →
  • Recruiting NCT NCT04877522

    Asciminib Roll-over Study

    Not yet reported Novartis Pharmaceuticals 347 participants Est. completion 2030-08-30 85 sites Stand-alone
    Other conditions: Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    View official trial listing →
  • Recruiting NCT NCT05036226

    COAST Therapy in Advanced Solid Tumors and Prostate Cancer

    Not yet reported, Not yet reported Medical University of South Carolina 76 participants Est. completion 2028-05-21 1 site Stand-alone
    Other conditions: Prostate Cancer Recurrent, Solid Tumor, Adult
    View official trial listing →
  • Recruiting NCT NCT05432518

    Pilot Trial for Treatment of Recurrent Glioblastoma

    Not yet reported AHS Cancer Control Alberta 10 participants Est. completion 2027-12-01 1 site Stand-alone
    Other conditions: Glioblastoma, Recurrent Disease, Recurrent Glioblastoma
    View official trial listing →
  • Recruiting NCT NCT05653258

    Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects

    Not yet reported, Not yet reported Cedars-Sinai Medical Center 160 participants Est. completion 2028-02-01 1 site Stand-alone
    Other conditions: Obesity, Healthy Lifestyle
    View official trial listing →
  • Recruiting NCT NCT05725200

    Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

    Not yet reported Oslo University Hospital 40 participants Est. completion 2040-12-31 1 site Stand-alone
    Other conditions: Metastatic Colorectal Cancer
    View official trial listing →
  • Recruiting NCT NCT05751044

    HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

    Not yet reported, Not yet reported Princess Maxima Center for Pediatric Oncology 26 participants Est. completion 2032-02-01 33 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
    View official trial listing →
  • Recruiting NCT NCT05751733

    Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

    Not yet reported Xiangya Hospital of Central South University 258 participants Est. completion 2027-01-01 1 site
    Other conditions: Gastrointestinal Stromal Tumors
    View official trial listing →
  • Recruiting NCT NCT06124157

    A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    Not yet reported National Cancer Institute (NCI) 222 participants Est. completion 2030-12-01 161 sites Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06257394

    Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea

    Not yet reported Hyoung Jin Kang 74 participants Est. completion 2034-12-31 10 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Pediatric
    View official trial listing →
  • Recruiting NCT NCT06336395

    Ma-Spore ALL 2020 Study

    Not yet reported National University Hospital, Singapore 500 participants Est. completion 2030-03 3 sites Stand-alone
    Other conditions: B Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06390319

    Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

    Not yet reported St. Jude Children's Research Hospital 100 participants Est. completion 2033-12 4 sites Stand-alone
    Other conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
    View official trial listing →
  • Recruiting NCT NCT06533748

    Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

    Not yet reported St. Jude Children's Research Hospital 128 participants Est. completion 2034-05 3 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06855810

    Newly-diagnosed Pediatric T-cell ALL Protocol

    Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 610 participants Est. completion 2031-06 27 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06940297

    Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Mayo Clinic 44 participants Est. completion 2031-08-15 1 site Stand-alone
    Other conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07025226

    Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease

    Not yet reported Mayo Clinic 30 participants Est. completion 2028-09-01 1 site Stand-alone
    Other conditions: Glioma
    View official trial listing →
  • Recruiting NCT NCT07091019

    A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

    Novartis Pharmaceuticals 1000 participants Est. completion 2033-04-20 17 sites
    Other conditions: Chronic Myelogenous Leukemia - Chronic Phase
    View official trial listing →
  • Recruiting NCT NCT07152041

    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 150 participants Est. completion 2030-06 24 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
    View official trial listing →
  • Recruiting NCT NCT07203352

    Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL

    Not yet reported Nanfang Hospital, Southern Medical University 154 participants Est. completion 2026-12-30 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT07269470

    Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

    Not yet reported M.D. Anderson Cancer Center 40 participants Est. completion 2029-11-01 1 site Stand-alone
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07342491

    Dasatinib for HIV-1 Reservoir Reduction

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 14 participants Est. completion 2027-05-12 3 sites Stand-alone
    Other conditions: HIV Infections
    View official trial listing →
  • Recruiting NCT NCT07549516

    A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany

    Novartis Pharmaceuticals 380 participants Est. completion 2030-09-30 69 sites
    Other conditions: Leukemia, Chronic Myeloid
    View official trial listing →
  • Completed NCT NCT00036738

    Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

    Not yet reported Fred Hutchinson Cancer Center 28 participants Est. completion 2018-05 3 sites Stand-alone
    Other conditions: Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blastic Phase, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Disease
    View official trial listing →
  • Completed NCT NCT00064233

    BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate

    Not yet reported Jonsson Comprehensive Cancer Center 42 participants Est. completion 2006-10 1 site
    Other conditions: Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT00070499

    Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

    Not yet reported National Cancer Institute (NCI) 406 participants Est. completion 2027-03-10 340 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia, BCR-ABL1 Positive
    View official trial listing →
  • Completed NCT NCT00099606

    Phase I (PH I) Mad Refractory Solid Tumor Study

    Not yet reported Bristol-Myers Squibb 60 participants Est. completion 2007-07 3 sites Stand-alone
    Other conditions: Neoplasms
    View official trial listing →
  • Completed NCT NCT00101595

    Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    Not yet reported Bristol-Myers Squibb 96 participants Est. completion 2007-12 60 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
    View official trial listing →
  • Completed NCT NCT00101647

    Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

    Not yet reported Bristol-Myers Squibb 197 participants Est. completion 2008-03 70 sites Stand-alone
    Other conditions: Chronic Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT00101660

    Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

    Not yet reported Bristol-Myers Squibb 387 participants Est. completion 2008-04 85 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00101816

    Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

    Not yet reported Bristol-Myers Squibb 124 participants Est. completion 2008-03 62 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia, Blast Crisis
    View official trial listing →
  • Completed NCT NCT00103701

    BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

    Not yet reported Bristol-Myers Squibb Est. completion 2006-03 2 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Chronic-phase, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
    View official trial listing →
  • Completed NCT NCT00103844

    Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

    Not yet reported Bristol-Myers Squibb 150 participants Est. completion 2008-03 131 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT00112775

    BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

    Not yet reported Jonsson Comprehensive Cancer Center 1 site
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00123474

    Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

    Not yet reported Bristol-Myers Squibb 724 participants Est. completion 2014-07 137 sites Stand-alone
    Other conditions: Myeloid Leukemia, Chronic, Chronic-Phase
    View official trial listing →
  • Completed NCT NCT00123487

    Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

    Not yet reported Bristol-Myers Squibb 638 participants Est. completion 2013-06 119 sites Stand-alone
    Other conditions: Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
    View official trial listing →
  • Terminated NCT NCT00162214

    Study of Dasatinib in Patients With Advanced Solid Tumors

    Not yet reported Bristol-Myers Squibb 60 participants Est. completion 2007-03 4 sites
    Other conditions: Tumors
    View official trial listing →
  • Completed NCT NCT00254423

    Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

    Not yet reported M.D. Anderson Cancer Center 150 participants Est. completion 2025-03-14 1 site Stand-alone
    Other conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT00255346

    Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

    Not yet reported M.D. Anderson Cancer Center 68 participants Est. completion 2017-03-03 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis, Hypereosinophilic Syndrome, Polycythemia Vera, Mastocytosis, Leukemia, Myelomonocytic, Chronic
    View official trial listing →
  • Completed NCT NCT00298987

    A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate

    Not yet reported Bristol-Myers Squibb 400 participants Est. completion 2007-06 35 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Chronic, Leukemia, Lymphocytic, Acute, L2
    View official trial listing →
  • Completed NCT NCT00306202

    Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia

    Not yet reported Bristol-Myers Squibb 63 participants Est. completion 2019-05-22 13 sites Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00316953

    Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

    Not yet reported National Cancer Institute (NCI) 48 participants 1 site Stand-alone
    Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Meningeal Chronic Myelogenous Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
    View official trial listing →
  • Terminated NCT NCT00320190

    Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

    Not yet reported Bristol-Myers Squibb 52 participants Est. completion 2010-01 27 sites
    Other conditions: Leukemia, Myeloid, Chronic
    View official trial listing →
  • Withdrawn NCT NCT00324077

    Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

    Not yet reported Bristol-Myers Squibb 3 sites
    Other conditions: Myeloid Leukemia, Chronic, Chronic-Phase
    View official trial listing →
  • Completed NCT NCT00337454

    Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan

    Not yet reported, Not yet reported Bristol-Myers Squibb 48 participants Est. completion 2007-03 21 sites Stand-alone
    Other conditions: Chronic Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT00339144

    Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

    Not yet reported Bristol-Myers Squibb 16 participants Est. completion 2008-09 2 sites Stand-alone
    Other conditions: Tumors
    View official trial listing →
  • Completed NCT NCT00345826

    Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

    Not yet reported Jonsson Comprehensive Cancer Center 19 participants 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Withdrawn NCT NCT00349518

    Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

    Not yet reported, Not yet reported Bristol-Myers Squibb 20 sites
    Other conditions: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
    View official trial listing →
  • Terminated NCT NCT00362466

    A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

    Not yet reported Bristol-Myers Squibb 3 participants Est. completion 2008-06 45 sites
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00364286

    Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

    Not yet reported M.D. Anderson Cancer Center 17 participants Est. completion 2012-11 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00371254

    A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

    Not yet reported Bristol-Myers Squibb 55 participants Est. completion 2008-09 10 sites Stand-alone
    Other conditions: Breast Cancer, Metastasis
    View official trial listing →
  • Completed NCT NCT00371345

    Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

    Not yet reported Bristol-Myers Squibb 92 participants Est. completion 2009-05 23 sites Stand-alone
    Other conditions: Breast Cancer, Metastasis
    View official trial listing →
  • Completed NCT NCT00382668

    A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

    Bristol-Myers Squibb 40 participants Est. completion 2007-08 4 sites
    Other conditions: Liver Diseases
    View official trial listing →
  • Completed NCT NCT00385580

    Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

    Not yet reported Bristol-Myers Squibb 94 participants Est. completion 2010-10 11 sites Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00388427

    Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies

    Not yet reported University of Pittsburgh 31 participants Est. completion 2013-02 1 site
    Other conditions: Malignant Solid Tumour
    View official trial listing →
  • Completed NCT NCT00390793

    Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

    Not yet reported M.D. Anderson Cancer Center 107 participants Est. completion 2024-02-02 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, t(9;22)
    View official trial listing →
  • Completed NCT NCT00391989

    Treatment of Adult Ph+ LAL With BMS-354825

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 53 participants Est. completion 2008-09 36 sites
    Other conditions: Lymphoblastic Leukemia, Acute
    View official trial listing →
  • Completed NCT NCT00410813

    S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

    Not yet reported SWOG Cancer Research Network 85 participants Est. completion 2014-01 117 sites Stand-alone
    Other conditions: Breast Cancer, Metastatic Cancer
    View official trial listing →
  • Completed NCT NCT00423735

    Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

    Not yet reported National Cancer Institute (NCI) 64 participants Est. completion 2018-09-04 188 sites Stand-alone
    Obstructive sleep apnea Other conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Recurrent Adult Brain Neoplasm
    View official trial listing →
  • Completed NCT NCT00429234

    Gemcitabine and Dasatinib in Advanced Solid Tumors

    Not yet reported M.D. Anderson Cancer Center 54 participants Est. completion 2013-02 1 site Stand-alone
    Other conditions: Advanced Cancer, Solid Tumors
    View official trial listing →
  • Completed NCT NCT00429949

    A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma

    Not yet reported Washington University School of Medicine 21 participants Est. completion 2008-01 1 site Stand-alone
    Other conditions: Relapsed, Refractory or Plateau Phase Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00436605

    Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma

    Not yet reported National Cancer Institute (NCI) 39 participants Est. completion 2010-11 2 sites Stand-alone
    Other conditions: Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
    View official trial listing →
  • Completed NCT NCT00438854

    Dasatinib in Relapsed Chronic Lymphocytic Leukemia

    Not yet reported Massachusetts General Hospital 15 participants Est. completion 2013-03 2 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00439270

    Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

    Not yet reported, Not yet reported Bristol-Myers Squibb 49 participants Est. completion 2013-01 5 sites
    Other conditions: Metastatic Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00444015

    Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 34 participants Est. completion 2010-08 1 site Stand-alone
    Other conditions: Non-Small-Cell Lung Carcinoma
    View official trial listing →
  • Completed NCT NCT00452673

    Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer

    Not yet reported Bristol-Myers Squibb 52 participants Est. completion 2012-10 7 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • No Longer Available NCT NCT00454753

    Expanded Access for Dasatinib

    Bristol-Myers Squibb
    View official trial listing →
  • Terminated NCT NCT00459108

    Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

    Not yet reported National Cancer Institute (NCI) 25 participants Est. completion 2011-04 1 site Stand-alone
    Other conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
    View official trial listing →
  • Completed NCT NCT00459342

    Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 35 participants Est. completion 2012-04 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00464620

    Trial of Dasatinib in Advanced Sarcomas

    Not yet reported Sarcoma Alliance for Research through Collaboration 366 participants Est. completion 2017-05 20 sites Stand-alone
    Obstructive sleep apnea Other conditions: Malignant Peripheral Nerve Sheath Tumors, Sarcoma, Ewing's, Sarcoma, Alveolar Soft Part, Chordoma, Epithelioid Sarcoma, Giant Cell Tumor of Bone, Hemangiopericytoma, Gastrointestinal Stromal Tumor (GIST)
    View official trial listing →
  • Completed NCT NCT00470054

    Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 44 participants Est. completion 2013-04 1 site Stand-alone
    Other conditions: Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00474812

    Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

    Not yet reported National Cancer Institute (NCI) 51 participants Est. completion 2014-02 1 site Stand-alone
    Other conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT00481247

    A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

    Not yet reported Bristol-Myers Squibb 547 participants Est. completion 2015-12 109 sites Stand-alone
    Other conditions: Myeloid Leukemia, Chronic
    View official trial listing →
  • Completed NCT NCT00482703

    A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

    Not yet reported, Not yet reported Bristol-Myers Squibb 23 participants Est. completion 2009-05 9 sites Stand-alone
    Other conditions: Myeloid Leukemia, Chronic
    View official trial listing →
  • Completed NCT NCT00495872

    Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

    Not yet reported M.D. Anderson Cancer Center 204 participants 1 site Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Terminated NCT NCT00500006

    A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

    Not yet reported Merck Sharp & Dohme LLC 3 participants Est. completion 2007-11
    Other conditions: Chronic Myelogenous Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
    View official trial listing →
  • Completed NCT NCT00501410

    FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

    Not yet reported M.D. Anderson Cancer Center 86 participants Est. completion 2017-03-03 1 site Stand-alone
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT00504153

    Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer

    Not yet reported National Cancer Institute (NCI) 19 participants Est. completion 2011-06 1 site Stand-alone
    Other conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
    View official trial listing →
  • Completed NCT NCT00507767

    Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

    Not yet reported National Cancer Institute (NCI) 15 participants Est. completion 2010-02 1 site Stand-alone
    Other conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
    View official trial listing →
  • Completed NCT NCT00509041

    Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

    Not yet reported Alliance for Clinical Trials in Oncology 46 participants Est. completion 2012-12 37 sites Stand-alone
    Other conditions: Malignant Mesothelioma
    View official trial listing →
  • Completed NCT NCT00529763

    Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects

    Not yet reported Bristol-Myers Squibb 121 participants Est. completion 2022-04-20 14 sites Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Terminated NCT NCT00538980

    Dasatinib in Polycythemia Vera

    Not yet reported Weill Medical College of Cornell University 10 participants Est. completion 2010-08-27 4 sites Stand-alone
    Other conditions: Polycythemia Vera
    View official trial listing →
  • Terminated NCT NCT00544908

    Dasatinib in Treating Patients With Stage IV Pancreatic Cancer

    Not yet reported City of Hope Medical Center 7 participants 2 sites Stand-alone
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT00546104

    Phase II Dasatinib Study in Advanced Breast Cancer

    Not yet reported Duke University 31 participants Est. completion 2011-05 3 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT00549848

    Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

    Not yet reported St. Jude Children's Research Hospital 600 participants Est. completion 2022-03-26 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT00550615

    Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

    Not yet reported, Not yet reported University of Nebraska 38 participants Est. completion 2017-12-01 1 site Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT00560352

    Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

    Not yet reported Bristol-Myers Squibb 16 participants Est. completion 2011-02 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00560391

    Dasatinib in Combination With Revlimid (and Dexamethasone)

    Not yet reported Bristol-Myers Squibb 35 participants Est. completion 2012-11 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00563290

    Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

    Not yet reported National Cancer Institute (NCI) 7 participants Est. completion 2014-10 3 sites Stand-alone
    Other conditions: Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT00564876

    Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer

    Not yet reported Duke University 2 participants Est. completion 2009-09 1 site Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Completed NCT NCT00566618

    Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 31 participants Est. completion 2020-11-17 3 sites Stand-alone
    Other conditions: Breast Cancer, Bone Metastases
    View official trial listing →
  • Completed NCT NCT00568750

    Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

    Not yet reported Swiss Cancer Institute 47 participants Est. completion 2018-05-16 18 sites Stand-alone
    Other conditions: Gastrointestinal Stromal Tumor
    View official trial listing →
  • Completed NCT NCT00570401

    Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

    Not yet reported Memorial Sloan Kettering Cancer Center 22 participants Est. completion 2011-09 1 site Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00570700

    Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

    Not yet reported University of California, Irvine 38 participants Est. completion 2012-02 6 sites Stand-alone
    Other conditions: Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Prostate Cancer, Recurrent Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00597038

    A Phase I/II Study of Dasatinib and Dacarbazine

    Not yet reported, Not yet reported H. Lee Moffitt Cancer Center and Research Institute 50 participants Est. completion 2011-09 2 sites Stand-alone
    Other conditions: Metastatic Melanoma
    View official trial listing →
  • Terminated NCT NCT00598091

    A Phase I/Expansion Study of Dasatinib

    Not yet reported Duke University 30 participants Est. completion 2012-05 3 sites
    Other conditions: Refractory Solid Tumors, Pancreatic Adenocarcinoma
    View official trial listing →
  • Completed NCT NCT00608361

    Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

    Not yet reported National Cancer Institute (NCI) 80 participants Est. completion 2014-08 23 sites Stand-alone
    Obstructive sleep apnea Other conditions: Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia, Adult Hepatocellular Carcinoma, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Adult T Acute Lymphoblastic Leukemia, Advanced Adult Hepatocellular Carcinoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Localized Non-Resectable Adult Liver Carcinoma, Localized Resectable Adult Liver Carcinoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Progressive Hairy Cell Leukemia Initial Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Liver Carcinoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Small Lymphocytic Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-Cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IIIA Mycosis Fungoides and Sezary Syndrome, Stage IIIB Mycosis Fungoides and Sezary Syndrome, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-Cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Stage IVA Mycosis Fungoides and Sezary Syndrome, Stage IVB Mycosis Fungoides and Sezary Syndrome, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Hairy Cell Leukemia, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00609999

    Ph I Dasatinib + Erlotinib in Recurrent MG

    Not yet reported Duke University 47 participants Est. completion 2010-07 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Glioblastoma
    View official trial listing →
  • Completed NCT NCT00624585

    Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 18 participants Est. completion 2012-05 1 site Stand-alone
    Other conditions: Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00652574

    Dasatinib in Resectable Malignant Pleural Mesothelioma

    Not yet reported M.D. Anderson Cancer Center 56 participants Est. completion 2022-10-07 1 site Stand-alone
    Other conditions: Malignant Pleural Mesothelioma
    View official trial listing →
  • Completed NCT NCT00655746

    The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects

    Not yet reported Bristol-Myers Squibb 14 participants Est. completion 2008-05 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00662636

    Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

    Not yet reported Mayo Clinic 27 participants Est. completion 2014-12-18 3 sites Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00671788

    A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

    Not yet reported Gynecologic Oncology Group 35 participants 20 sites Stand-alone
    Other conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
    View official trial listing →
  • Completed NCT NCT00672295

    PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer

    Not yet reported AA Secord 11 participants Est. completion 2012-11 2 sites Stand-alone
    Other conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
    View official trial listing →
  • Terminated NCT NCT00688766

    Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

    Not yet reported Infinity Pharmaceuticals, Inc. 47 participants Est. completion 2009-05 Stand-alone
    Other conditions: Gastrointestinal Stromal Tumors
    View official trial listing →
  • Completed NCT NCT00696072

    Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

    Not yet reported Bristol-Myers Squibb 120 participants Est. completion 2014-06 27 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00700882

    Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

    Not yet reported Eastern Cooperative Oncology Group 81 participants Est. completion 2020-12-28 153 sites Stand-alone
    Other conditions: Melanoma (Skin)
    View official trial listing →
  • Completed NCT NCT00706641

    Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder

    Not yet reported Hoosier Cancer Research Network 25 participants Est. completion 2012-12 3 sites Stand-alone
    Other conditions: Transitional Cell Carcinoma of the Bladder
    View official trial listing →
  • Completed NCT NCT00717704

    Solid Tumors Using Ixabepilone and Dasatinib

    Not yet reported Medstar Health Research Institute 19 participants Est. completion 2011-05 1 site Stand-alone
    Other conditions: Solid Tumor
    View official trial listing →
  • Completed NCT NCT00720109

    Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    Not yet reported, Not yet reported National Cancer Institute (NCI) 63 participants Est. completion 2020-03-31 134 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
    View official trial listing →
  • Withdrawn NCT NCT00732186

    Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

    Not yet reported Bristol-Myers Squibb Est. completion 2011-02 1 site
    Other conditions: Leukemia, Myeloid, Chronic
    View official trial listing →
  • Withdrawn NCT NCT00734864

    Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

    Not yet reported Annick Desjardins Est. completion 2012-06 1 site
    Obstructive sleep apnea Other conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioma
    View official trial listing →
  • Completed NCT NCT00744497

    Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer

    Not yet reported Bristol-Myers Squibb 1930 participants Est. completion 2015-07 186 sites
    Other conditions: Prostatic Neoplasms
    View official trial listing →
  • Completed NCT NCT00754325

    Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

    Not yet reported Bristol-Myers Squibb 100 participants Est. completion 2014-01 28 sites
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT00764309

    Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

    Not yet reported, Not yet reported Bristol-Myers Squibb 47 participants Est. completion 2011-04 13 sites Stand-alone
    Other conditions: Scleroderma
    View official trial listing →
  • Completed NCT NCT00767520

    Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

    Not yet reported Bristol-Myers Squibb 155 participants Est. completion 2012-12 21 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00777036

    A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

    Not yet reported Bristol-Myers Squibb 133 participants Est. completion 2025-01-27 174 sites Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00779389

    Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

    Not yet reported University of Pittsburgh 58 participants Est. completion 2014-02 1 site Stand-alone
    Other conditions: Head and Neck Cancer, Non Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT00780676

    Personalized Treatment Selection for Metastatic Breast Cancer

    Not yet reported M.D. Anderson Cancer Center 97 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00787267

    Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

    Not yet reported Duke University 37 participants Est. completion 2013-06 3 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT00787852

    A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)

    Not yet reported Brown University 11 participants Est. completion 2011-12 1 site Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT00788125

    Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

    Not yet reported, Not yet reported City of Hope Medical Center 7 participants Est. completion 2022-07-30 1 site Stand-alone
    Other conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
    View official trial listing →
  • Active, not recruiting NCT NCT00792948

    Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

    Not yet reported National Cancer Institute (NCI) 97 participants Est. completion 2027-01-06 157 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT00816283

    Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

    Not yet reported City of Hope Medical Center 5 participants Est. completion 2011-06 2 sites
    Other conditions: Leukemia
    View official trial listing →
  • Terminated NCT NCT00817531

    Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

    Not yet reported Baylor Breast Care Center 22 participants Est. completion 2011-02 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00820170

    Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 55 participants Est. completion 2018-08 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00826449

    Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 53 participants Est. completion 2014-06 1 site Stand-alone
    Other conditions: Lung Cancer, Non-Small Cell Lung Cancer
    View official trial listing →
  • Withdrawn NCT NCT00829647

    A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

    Not yet reported, Not yet reported Scripps Health Est. completion 2016-03-01 Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Leukemia
    View official trial listing →
  • Terminated NCT NCT00835679

    Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery

    Not yet reported National Cancer Institute (NCI) 9 participants Est. completion 2011-08 2 sites Stand-alone
    Other conditions: Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
    View official trial listing →
  • Completed NCT NCT00850382

    Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

    Not yet reported, Not yet reported University of Ulm 89 participants Est. completion 2015-11 50 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Completed NCT NCT00852566

    Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia

    Not yet reported Norwegian University of Science and Technology 46 participants Est. completion 2015-12 7 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Available NCT NCT00854841

    The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

    Pusan National University Hospital
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT00858403

    Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 7 participants Est. completion 2010-07 1 site Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00859937

    Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

    Not yet reported National Cancer Institute (NCI) 55 participants 34 sites Stand-alone
    Other conditions: Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v7
    View official trial listing →
  • Terminated NCT NCT00860158

    Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

    Not yet reported Noah Hahn, M.D. 1 participants Est. completion 2010-12 6 sites Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT00860535

    Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)

    Not yet reported Merck Sharp & Dohme LLC 9 participants Est. completion 2010-06 Stand-alone
    Other conditions: Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)
    View official trial listing →
  • Completed NCT NCT00866736

    A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia

    Not yet reported Kanto CML Study Group 65 participants Est. completion 2012-06 1 site Stand-alone
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00869401

    Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

    Not yet reported, Not yet reported Alliance for Clinical Trials in Oncology 217 participants Est. completion 2019-11-15 207 sites Stand-alone
    Other conditions: Brain and Central Nervous System Tumors
    View official trial listing →
  • Withdrawn NCT NCT00872976

    Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

    Not yet reported Bristol-Myers Squibb Est. completion 2011-12 3 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT00882583

    A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 22 participants Est. completion 2016-02 2 sites Stand-alone
    Other conditions: Head and Neck Cancer
    View official trial listing →
  • Completed NCT NCT00892177

    Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme

    Not yet reported Alliance for Clinical Trials in Oncology 144 participants Est. completion 2019-07-01 305 sites Stand-alone
    Other conditions: Glioblastoma Multiforme
    View official trial listing →
  • Completed NCT NCT00892190

    Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome

    Not yet reported University of Pittsburgh 9 participants Est. completion 2016-02 1 site Stand-alone
    Other conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00895128

    Study of Erlotinib in Combination With Dasatinib

    Not yet reported M.D. Anderson Cancer Center 65 participants 1 site Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Terminated NCT NCT00895297

    Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia

    Not yet reported European Society for Blood and Marrow Transplantation 50 participants Est. completion 2011-11 7 sites
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT00895960

    Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma

    Not yet reported M.D. Anderson Cancer Center 16 participants Est. completion 2013-08 1 site Stand-alone
    Other conditions: Glioblastoma, CNS Disease, Brain Diseases
    View official trial listing →
  • Terminated NCT NCT00903006

    Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 11 participants Est. completion 2013-05 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00903734

    An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

    Not yet reported M.D. Anderson Cancer Center 16 participants 1 site
    Other conditions: Advanced Cancers
    View official trial listing →
  • Terminated NCT NCT00918385

    Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

    Not yet reported Duke University 57 participants Est. completion 2013-08 3 sites
    Other conditions: Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT00918463

    A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    Not yet reported Weill Medical College of Cornell University 2 participants Est. completion 2011-05-23 1 site Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00920868

    XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

    Not yet reported Herbert Hurwitz, MD 22 participants Est. completion 2014-08 2 sites Stand-alone
    Other conditions: Solid Tumor, Metastatic Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT00924352

    Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

    Not yet reported, Not yet reported Accelerated Community Oncology Research Network 56 participants Est. completion 2013-10 13 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT00936975

    Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

    Not yet reported National Cancer Institute (NCI) 18 participants Est. completion 2014-12 4 sites Stand-alone
    Other conditions: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00940524

    Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

    Not yet reported Memorial Sloan Kettering Cancer Center 7 participants Est. completion 2014-04 1 site Stand-alone
    Other conditions: Leukemia, Acute Lymphoblastic Leukemia
    View official trial listing →
  • Terminated NCT NCT00948389

    Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

    Not yet reported, Not yet reported Bristol-Myers Squibb 28 participants Est. completion 2011-05 5 sites
    Other conditions: Glioblastoma
    View official trial listing →
  • Terminated NCT NCT00949988

    A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia

    Not yet reported, Not yet reported University of California, San Diego 3 participants Est. completion 2012-04 1 site
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00978731

    Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study

    Not yet reported Bristol-Myers Squibb 46 participants Est. completion 2008-09 Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Status unknown NCT NCT00979160

    Evaluation of Response of Dasatinib to Treat Mastocytosis

    Not yet reported Federico II University 30 participants Est. completion 2012-12 12 sites Stand-alone
    Other conditions: Systemic Mastocytosis
    View official trial listing →
  • Completed NCT NCT00982488

    Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    Not yet reported Bristol-Myers Squibb 238 participants Est. completion 2014-12 72 sites
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00996723

    Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

    Not yet reported St. Jude Children's Research Hospital 25 participants Est. completion 2014-06 1 site
    Other conditions: Diffuse Intrinsic Pontine Glioma
    View official trial listing →
  • Completed NCT NCT01004497

    First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

    Not yet reported The Catholic University of Korea 51 participants Est. completion 2015-04 8 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT01015222

    Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

    Not yet reported M.D. Anderson Cancer Center 122 participants Est. completion 2021-05-27 1 site Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT01030718

    Rollover Study of BMS-354825 in Patients With CML and Ph+ALL

    Not yet reported, Not yet reported Bristol-Myers Squibb 54 participants Est. completion 2009-06 Stand-alone
    Other conditions: Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    View official trial listing →
  • Status unknown NCT NCT01051115

    Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease

    Not yet reported Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 35 participants Est. completion 2016-01 4 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT01073436

    Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha

    University of Michigan Rogel Cancer Center 7 participants Est. completion 2011-11 1 site
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01077544

    A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

    Not yet reported Novartis Pharmaceuticals 15 participants Est. completion 2015-07-01 12 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
    View official trial listing →
  • Terminated NCT NCT01092728

    Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

    Not yet reported M.D. Anderson Cancer Center 19 participants Est. completion 2014-08 1 site
    Other conditions: Melanoma
    View official trial listing →
  • Completed NCT NCT01098500

    Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs

    GlaxoSmithKline 3800 participants Est. completion 2010-10
    Other conditions: Cancer
    View official trial listing →
  • Terminated NCT NCT01116128

    Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients

    Not yet reported Fondazione EMN Italy Onlus 8 participants Est. completion 2011-05 1 site Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Terminated NCT NCT01169753

    Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients

    Not yet reported M.D. Anderson Cancer Center 1 participants Est. completion 2013-02 1 site
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT01173679

    Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

    Not yet reported Massachusetts General Hospital 10 participants Est. completion 2015-01 3 sites
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT01188278

    Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

    Bristol-Myers Squibb 173 participants Est. completion 2013-01
    Other conditions: Leukemia, Myeloid, Chronic-Phase (CML-CP)
    View official trial listing →
  • Completed NCT NCT01207440

    Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)

    Not yet reported Ariad Pharmaceuticals 449 participants Est. completion 2019-01-17 42 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT01218477

    Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

    Not yet reported, Not yet reported Bristol-Myers Squibb 33 participants Est. completion 2013-04 12 sites Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT01234935

    Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

    Not yet reported Translational Oncology Research International 8 participants Est. completion 2017-11-27 17 sites Stand-alone
    Other conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT01238211

    Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

    Not yet reported National Cancer Institute (NCI) 61 participants Est. completion 2021-03-15 65 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Core Binding Factor Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01244750

    Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

    Bristol-Myers Squibb 1494 participants Est. completion 2020-01-08 214 sites
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01254864

    Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

    Not yet reported M.D. Anderson Cancer Center 190 participants Est. completion 2023-12-07 1 site Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT01256398

    Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    Not yet reported National Cancer Institute (NCI) 66 participants Est. completion 2021-11-15 101 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
    View official trial listing →
  • Completed NCT NCT01260688

    Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

    Not yet reported National Cancer Institute (NCI) 22 participants Est. completion 2014-02 8 sites Stand-alone
    Other conditions: Hormone Refractory Prostate Cancer, Recurrent Prostate Cancer
    View official trial listing →
  • Completed NCT NCT01306942

    Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

    Not yet reported, Not yet reported Spanish Breast Cancer Research Group 37 participants Est. completion 2019-03-15 8 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT01310010

    Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia

    Not yet reported Grupo Espanol de trasplantes hematopoyeticos y terapia celular 30 participants Est. completion 2016-07 1 site Stand-alone
    Other conditions: Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
    View official trial listing →
  • Completed NCT NCT01342679

    A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

    Not yet reported Kanto CML Study Group 21 participants Est. completion 2014-09 1 site Stand-alone
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT01357655

    Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

    Not yet reported Bristol-Myers Squibb 70 participants Est. completion 2016-01 24 sites Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT01392703

    Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

    Not yet reported Bristol-Myers Squibb 141 participants Est. completion 2011-09 1 site
    Other conditions: Pharmacokinetic Study in Healthy Participants
    View official trial listing →
  • Completed NCT NCT01395017

    Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 202 participants Est. completion 2015-03 74 sites
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Terminated NCT NCT01397734

    Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)

    Not yet reported Beth Israel Deaconess Medical Center 7 participants Est. completion 2018-08-06 1 site Stand-alone
    Other conditions: Chronic Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT01398046

    Effects of Gastric pH on the Pharmacokinetics of Dasatinib

    Not yet reported University of California, San Francisco 10 participants Est. completion 2014-02 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Withdrawn NCT NCT01410708

    TORI 104 Pre-Surgical Dasatinib

    Not yet reported AHS Cancer Control Alberta 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT01426334

    Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

    Not yet reported National Cancer Institute (NCI) 4 participants 2 sites Stand-alone
    Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT01440998

    Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

    Not yet reported National Cancer Institute (NCI) 18 participants Est. completion 2015-12-31 1 site Stand-alone
    Other conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
    View official trial listing →
  • Completed NCT NCT01441882

    Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia

    Not yet reported OHSU Knight Cancer Institute 19 participants Est. completion 2018-01-01 1 site Stand-alone
    Other conditions: Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01445509

    Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

    Not yet reported National Cancer Institute (NCI) 50 participants Est. completion 2018-09-20 1 site Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT01460160

    Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

    Not yet reported Bristol-Myers Squibb 106 participants Est. completion 2021-06-01 128 sites Stand-alone
    Other conditions: Leukemia, Pediatric
    View official trial listing →
  • Completed NCT NCT01460693

    Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia

    Not yet reported Newcastle University 814 participants Est. completion 2018-03-07 1 site Stand-alone
    Other conditions: Myeloid Leukemia, Chronic, Chronic Phase
    View official trial listing →
  • Completed NCT NCT01464047

    Korean Post-marketing Surveillance for Sprycel®

    Bristol-Myers Squibb 670 participants Est. completion 2015-08 1 site
    Other conditions: Leukemia, Myelomonocytic, Chronic, Leukemia-Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01464411

    Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan

    Kanto CML Study Group 40 participants 1 site
    Other conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myelogenous Leukemia, Chronic, Chronic Phase
    View official trial listing →
  • Completed NCT NCT01467986

    Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma

    Not yet reported University of Regensburg 130 participants Est. completion 2020-09-30 1 site Stand-alone
    Other conditions: Neuroblastoma Recurrent
    View official trial listing →
  • Completed NCT NCT01471106

    Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

    Not yet reported M.D. Anderson Cancer Center 26 participants Est. completion 2024-05-30 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01475110

    Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib

    Gruppo Italiano Malattie EMatologiche dell'Adulto 19 participants Est. completion 2016-11-24 33 sites
    Other conditions: Chronic Myeloid Leukaemia
    View official trial listing →
  • Completed NCT NCT01482728

    Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer

    Not yet reported University of Virginia 12 participants Est. completion 2015-12 1 site
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Terminated NCT NCT01488318

    Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

    Not yet reported Julie E. Bauman, MD, MPH 21 participants Est. completion 2016-08 1 site Stand-alone
    Other conditions: Squamous Cell Carcinoma Of The Head And Neck
    View official trial listing →
  • Terminated NCT NCT01491633

    Dasatinib in Advanced Squamous Cell Lung Cancer

    Not yet reported Dana-Farber Cancer Institute 5 participants Est. completion 2013-05 3 sites Stand-alone
    Other conditions: Squamous Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT01498445

    An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 32 participants Est. completion 2019-09-24 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Terminated NCT NCT01514864

    Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

    Not yet reported Bristol-Myers Squibb 19 participants Est. completion 2014-07-23 24 sites Stand-alone
    Other conditions: Carcinoma, Non-small Cell Lung
    View official trial listing →
  • No Longer Available NCT NCT01549548

    Compassionate Use Ponatinib

    OHSU Knight Cancer Institute 1 site
    Other conditions: Philadelphia Chromosome Positive (Ph+) Leukemias, Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01593254

    Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib

    Not yet reported Bristol-Myers Squibb 262 participants Est. completion 2022-04-12 101 sites
    Other conditions: Chronic Phase Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01602952

    Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

    Not yet reported, Not yet reported Il-Yang Pharm. Co., Ltd. 85 participants Est. completion 2018-07-13 12 sites
    Other conditions: Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Philadelphia Chromosome, Hematologic Diseases
    View official trial listing →
  • Completed NCT NCT01606579

    Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

    Not yet reported, Not yet reported Prism Pharma Co., Ltd. 49 participants Est. completion 2016-12-30 6 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Chronic Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT01609816

    Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

    Not yet reported Barbara Ann Karmanos Cancer Institute 8 participants Est. completion 2018-10-09 1 site Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma, Multiple, Mycosis Fungoides, Hodgkin's Lymphoma, Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01620216

    Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

    Not yet reported OHSU Knight Cancer Institute 12 participants Est. completion 2017-04-30 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT01627132

    Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

    Not yet reported Shimousa Hematology Study Group 50 participants Est. completion 2019-01 1 site Stand-alone
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01636908

    Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

    Not yet reported Amsterdam UMC, location VUmc 43 participants Est. completion 2019-12-01 1 site Stand-alone
    Other conditions: Cancer, Advanced Solid Tumors
    View official trial listing →
  • Completed NCT NCT01643278

    Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic

    Not yet reported National Cancer Institute (NCI) 29 participants Est. completion 2016-06 1 site Stand-alone
    Other conditions: Gastrointestinal Stromal Tumor, Stage III Soft Tissue Sarcoma, Stage IV Soft Tissue Sarcoma
    View official trial listing →
  • Terminated NCT NCT01643603

    Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

    Not yet reported Barbara Ann Karmanos Cancer Institute 5 participants Est. completion 2018-10-09 1 site Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Lymphoid Leukemia
    View official trial listing →
  • Completed NCT NCT01644773

    Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

    Not yet reported St. Jude Children's Research Hospital 36 participants Est. completion 2018-09-28 1 site Stand-alone
    Other conditions: Diffuse Intrinsic Pontine Glioma, High-grade Glioma
    View official trial listing →
  • Completed NCT NCT01652976

    Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma

    Not yet reported University of Florida 44 participants Est. completion 2020-07 1 site Stand-alone
    Other conditions: Pancreatic Cancer Metastatic
    View official trial listing →
  • Completed NCT NCT01660906

    Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

    Not yet reported Bristol-Myers Squibb 39 participants Est. completion 2015-10 22 sites Stand-alone
    Other conditions: Chronic Phase Chronic Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT01660971

    Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

    Not yet reported National Cancer Institute (NCI) 19 participants Est. completion 2027-03-31 1 site Stand-alone
    Other conditions: Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT01667133

    A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

    Not yet reported, Not yet reported Ariad Pharmaceuticals 35 participants Est. completion 2018-08-02 11 sites
    Other conditions: Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    View official trial listing →
  • Status unknown NCT NCT01685125

    Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

    Not yet reported University of Southern California 96 participants Est. completion 2018-03 1 site Stand-alone
    Other conditions: Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
    View official trial listing →
  • Completed NCT NCT01703910

    Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic

    Not yet reported Centro Nacional de Investigaciones Oncologicas CARLOS III 29 participants Est. completion 2014-12 2 sites
    Other conditions: Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease
    View official trial listing →
  • Completed NCT NCT01724879

    Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)

    Not yet reported Goethe University 19 participants Est. completion 2015-09 22 sites Stand-alone
    Other conditions: Philadelphia Positive Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT01725204

    Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia

    Not yet reported Norwegian University of Science and Technology 40 participants Est. completion 2016-05 14 sites Stand-alone
    Other conditions: Leukemia, Myeloid, Chronic-Phase
    View official trial listing →
  • Completed NCT NCT01744652

    Dasatinib and Crizotinib in Advanced Cancer

    Not yet reported M.D. Anderson Cancer Center 62 participants Est. completion 2019-03 1 site Stand-alone
    Other conditions: Advanced Cancers
    View official trial listing →
  • Terminated NCT NCT01751425

    Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

    Not yet reported M.D. Anderson Cancer Center 8 participants Est. completion 2019-09-24 1 site Stand-alone
    Other conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual Disease, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
    View official trial listing →
  • Status unknown NCT NCT01761890

    Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib

    Gruppo Italiano Malattie EMatologiche dell'Adulto 147 participants Est. completion 2022-12 37 sites
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01771458

    A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

    Not yet reported Institut Curie 742 participants Est. completion 2016-12 8 sites Stand-alone
    Other conditions: Reccurent/Metastatic Solid Tumor Disease
    View official trial listing →
  • Status unknown NCT NCT01802450

    Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

    Not yet reported PETHEMA Foundation 18 participants Est. completion 2016-12 15 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01804985

    De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia

    Not yet reported University of Liverpool 174 participants Est. completion 2018-06 1 site Stand-alone
    Other conditions: Chronic Myeloid Leukaemia
    View official trial listing →
  • Completed NCT NCT01805843

    Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia

    Medical University of Graz 16 participants Est. completion 2015-06 1 site
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Withdrawn NCT NCT01826838

    Study of Dasatinib, Androgen Deprivation Therapy and Radiation

    Not yet reported Brown University Est. completion 2013-04 Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT01844765

    Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

    Not yet reported Novartis Pharmaceuticals 59 participants Est. completion 2020-08-28 36 sites Stand-alone
    Other conditions: Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT01850004

    Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

    Not yet reported Bristol-Myers Squibb 84 participants Est. completion 2021-10-08 28 sites Stand-alone
    Other conditions: Chronic Phase Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01872442

    Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase

    Not yet reported Poitiers University Hospital Est. completion 2018-10-31 Stand-alone
    Other conditions: Chronic Phase of Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01876212

    Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

    Not yet reported Walter J. Storkus 15 participants Est. completion 2019-07-31 1 site Stand-alone
    Other conditions: Metastatic Melanoma
    View official trial listing →
  • Terminated NCT NCT01876953

    Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia

    Not yet reported, Not yet reported City of Hope Medical Center 20 participants Est. completion 2018-04-25 1 site Stand-alone
    Other conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT01883219

    TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

    Not yet reported Nanfang Hospital, Southern Medical University 80 participants Est. completion 2017-11 1 site Stand-alone
    Other conditions: Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation, Minimal Residual Disease
    View official trial listing →
  • Status unknown NCT NCT01887561

    Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

    Not yet reported Kanto CML Study Group 100 participants 1 site
    Other conditions: Myelogenous Leukemia, Chronic, Chronic Phase
    View official trial listing →
  • Completed NCT NCT01916135

    PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative

    Not yet reported Memorial Sloan Kettering Cancer Center 11 participants Est. completion 2020-04-23 1 site Stand-alone
    Other conditions: Carcinoma, Sarcoma, Myeloma, Lymphoma, Melanoma
    View official trial listing →
  • Completed NCT NCT01916785

    OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)

    Not yet reported Versailles Hospital 289 participants Est. completion 2013-12 34 sites Stand-alone
    Other conditions: Chronic Myelogenous Leukemia, BCR/ABL Positive
    View official trial listing →
  • Active, not recruiting NCT NCT01990196

    Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

    Not yet reported Jonsson Comprehensive Cancer Center 45 participants Est. completion 2026-09-30 1 site
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT01999985

    Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 25 participants Est. completion 2019-05-30 1 site Stand-alone
    Other conditions: Lung Cancer, Non-small Cell Lung Cancer (NSCLC)
    View official trial listing →
  • Completed NCT NCT02011945

    A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

    Not yet reported Bristol-Myers Squibb 35 participants Est. completion 2018-12-26 21 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT02013648

    Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

    Not yet reported University of Ulm 204 participants Est. completion 2024-02 54 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Status unknown NCT NCT02015728

    Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

    Not yet reported Seattle Children's Hospital 20 participants Est. completion 2017-12 1 site Stand-alone
    Other conditions: Recurrent Childhood Brain Tumor
    View official trial listing →
  • Terminated NCT NCT02043587

    Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

    Not yet reported University of California, San Diego 31 participants Est. completion 2022-04-14 4 sites Stand-alone
    Other conditions: Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
    View official trial listing →
  • Terminated NCT NCT02047149

    Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia

    Not yet reported University of Massachusetts, Worcester 2 participants Est. completion 2016-06 1 site Stand-alone
    Other conditions: Chronic Myelogenous Leukemia
    View official trial listing →
  • Terminated NCT NCT02059265

    Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

    Not yet reported National Cancer Institute (NCI) 35 participants Est. completion 2023-06-26 227 sites Stand-alone
    Other conditions: Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Cancer
    View official trial listing →
  • Completed NCT NCT02081378

    A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

    Not yet reported Novartis Pharmaceuticals 326 participants Est. completion 2023-03-14 18 sites Stand-alone
    Other conditions: Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
    View official trial listing →
  • Terminated NCT NCT02108951

    Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.

    Not yet reported Novartis Pharmaceuticals 20 participants Est. completion 2016-08-10 14 sites Stand-alone
    Other conditions: Philidelphia Positive Chronic Myeloid Leukaemia
    View official trial listing →
  • Completed NCT NCT02113319

    Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia

    Not yet reported University Hospital, Angers 27 participants 1 site Stand-alone
    Other conditions: Acute Myelogenous Leukemia
    View official trial listing →
  • Withdrawn NCT NCT02129166

    Explore the Synergy of Combination TKI Therapy

    Not yet reported University of Florida Est. completion 2014-10
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02142036

    N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy

    Not yet reported Oslo University Hospital 50 participants Est. completion 2018-08 2 sites
    Other conditions: Metastatic Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02143414

    Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

    Not yet reported National Cancer Institute (NCI) 53 participants Est. completion 2027-06-06 195 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
    View official trial listing →
  • Status unknown NCT NCT02164903

    LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients

    Gruppo Italiano Malattie EMatologiche dell'Adulto 323 participants Est. completion 2018-10 49 sites
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT02222272

    Effect of 2nd Gen TKI in CML

    European Society for Blood and Marrow Transplantation 432 participants Est. completion 2017-09-29 10 sites
    Other conditions: Myeloid Leukemia, Chronic
    View official trial listing →
  • Status unknown NCT NCT02233049

    Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris 250 participants Est. completion 2018-10 1 site Stand-alone
    Other conditions: Diffuse Intrinsic Pontine Glioma
    View official trial listing →
  • Status unknown NCT NCT02268370

    Treatment-free Remission Accomplished With Dasatinib in Patients With CML

    Not yet reported University Health Network, Toronto 131 participants Est. completion 2021-10 12 sites
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT02269267

    The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

    Not yet reported Medical College of Wisconsin 173 participants Est. completion 2022-04-06 16 sites
    Other conditions: Leukemia, Myeloid, Chronic
    View official trial listing →
  • Completed NCT NCT02297139

    Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

    Not yet reported Bristol-Myers Squibb 17 participants Est. completion 2022-05-15 6 sites Stand-alone
    Other conditions: Multiple Indications Cancer
    View official trial listing →
  • Completed NCT NCT02326311

    Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

    Not yet reported Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia 229 participants Est. completion 2024-05-29 1 site Stand-alone
    Other conditions: Leukemia, Chronic Myeloid
    View official trial listing →
  • Completed NCT NCT02348957

    Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib

    Onco Medical Consult GmbH 223 participants Est. completion 2019-05 66 sites
    Other conditions: Myeloid Leukemia, Chronic, Chronic-Phase
    View official trial listing →
  • Completed NCT NCT02363868

    Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population

    Bristol-Myers Squibb 186 participants Est. completion 2014-11 1 site
    Other conditions: Chronic Myeloid Leukemia (CML)
    View official trial listing →
  • Active, not recruiting NCT NCT02389309

    Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

    Not yet reported M.D. Anderson Cancer Center 14 participants Est. completion 2027-10-31 1 site Stand-alone
    Other conditions: Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Brain Neoplasm
    View official trial listing →
  • Status unknown NCT NCT02389920

    Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

    Not yet reported Samsung Medical Center 40 participants Est. completion 2018-12
    Other conditions: Leukemia, Chronic Myeloid
    View official trial listing →
  • Completed NCT NCT02389972

    Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

    Bristol-Myers Squibb 128 participants Est. completion 2017-07-13 1 site
    Other conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    View official trial listing →
  • Terminated NCT NCT02420717

    Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

    Not yet reported M.D. Anderson Cancer Center 11 participants Est. completion 2021-01-20 1 site Stand-alone
    Other conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Ph-Like Acute Lymphoblastic Leukemia
    View official trial listing →
  • Withdrawn NCT NCT02421926

    Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)

    Asan Medical Center Est. completion 2023-05 12 sites
    Other conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    View official trial listing →
  • Completed NCT NCT02428855

    Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

    Not yet reported Massachusetts General Hospital 8 participants Est. completion 2018-02 2 sites Stand-alone
    Other conditions: Cholangiocarcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT02465060

    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    Not yet reported National Cancer Institute (NCI) 6452 participants Est. completion 2027-12-31 1410 sites Stand-alone
    Other conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT02494882

    Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

    Not yet reported Memorial Sloan Kettering Cancer Center 12 participants Est. completion 2027-06 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT02523976

    Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 30 participants Est. completion 2021-12-31 1 site Stand-alone
    Other conditions: Acute,Leukemia, Lymphoid
    View official trial listing →
  • Completed NCT NCT02546791

    Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study

    Bristol-Myers Squibb 101 participants Est. completion 2017-03-29
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT02551718

    High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

    Not yet reported University of Washington 34 participants Est. completion 2021-05-13 1 site Stand-alone
    Other conditions: Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
    View official trial listing →
  • Completed NCT NCT02596828

    Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma

    Not yet reported University of Regensburg 4 participants Est. completion 2021-04 1 site Stand-alone
    Other conditions: Pineoblastoma
    View official trial listing →
  • Status unknown NCT NCT02638428

    Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

    Not yet reported Samsung Medical Center 90 participants Est. completion 2023-12 1 site Stand-alone
    Other conditions: Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Relapsed Pediatric AML, Refractory Pediatric AML
    View official trial listing →
  • Completed NCT NCT02652052

    Hematopoietic Stem Cell Transplant Survivors Study

    Not yet reported Mayo Clinic 9 participants Est. completion 2023-05-23 1 site Stand-alone
    Other conditions: Stem Cell Transplant
    View official trial listing →
  • Withdrawn NCT NCT02680951

    Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

    Not yet reported Emory University Est. completion 2017-12-15 Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT02689440

    Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

    Not yet reported M.D. Anderson Cancer Center 155 participants Est. completion 2040-12-31 1 site Stand-alone
    Other conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
    View official trial listing →
  • Status unknown NCT NCT02690922

    Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients

    Not yet reported Tongji Hospital 40 participants Est. completion 2017-05 1 site Stand-alone
    Other conditions: ph+ Acute Lymphoblastic Leukemia
    View official trial listing →
  • Terminated NCT NCT02709083

    Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

    Not yet reported Emory University 7 participants Est. completion 2018-07 1 site Stand-alone
    Other conditions: Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Leukemia
    View official trial listing →
  • Terminated NCT NCT02720185

    Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

    Not yet reported University of Wisconsin, Madison 5 participants Est. completion 2022-02-08 2 sites Stand-alone
    Other conditions: Breast Neoplasms, Triple Negative Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT02733445

    Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

    Bristol-Myers Squibb 2650 participants Est. completion 2016-03
    Other conditions: Chronic Myeloid Leukemia (CML)
    View official trial listing →
  • Status unknown NCT NCT02744768

    D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 60 participants Est. completion 2021-06 34 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Terminated NCT NCT02750514

    An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

    Not yet reported Bristol-Myers Squibb 295 participants Est. completion 2020-01-29 50 sites Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Status unknown NCT NCT02776878

    A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST

    Not yet reported Peking University Cancer Hospital & Institute 57 participants Est. completion 2018-05 7 sites Stand-alone
    Other conditions: Gastrointestinal Stromal Tumor
    View official trial listing →
  • Completed NCT NCT02779283

    Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

    Not yet reported OHSU Knight Cancer Institute 7 participants Est. completion 2018-09-20 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT02788201

    Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

    Not yet reported National Cancer Institute (NCI) 8 participants Est. completion 2019-10-23 1 site Stand-alone
    Other conditions: Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
    View official trial listing →
  • Withdrawn NCT NCT02815059

    Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

    Not yet reported University of Utah Est. completion 2018-01-09 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Terminated NCT NCT02819804

    Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

    Not yet reported Northwestern University 1 participants Est. completion 2018-08-30 1 site Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Refractory Childhood Acute Lymphoblastic Leukemia
    View official trial listing →
  • Enrolling by invitation NCT NCT02848131

    Senescence in Chronic Kidney Disease

    Not yet reported Mayo Clinic 30 participants Est. completion 2027-04 2 sites
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT02874989

    Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial

    Not yet reported Wake Forest University Health Sciences 26 participants Est. completion 2019-06-03 2 sites Stand-alone
    Other conditions: Idiopathic Pulmonary Fibrosis (IPF)
    View official trial listing →
  • Completed NCT NCT02883049

    Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

    Not yet reported National Cancer Institute (NCI) 5949 participants Est. completion 2026-03-31 239 sites Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
    View official trial listing →
  • Completed NCT NCT02888990

    Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia

    Not yet reported Versailles Hospital 71 participants Est. completion 2016-01 64 sites Stand-alone
    Other conditions: Leukemia, Lymphoblastic, Acute
    View official trial listing →
  • Completed NCT NCT02890784

    Dasatinib Holiday for Improved Tolerability

    Not yet reported University of Jena 291 participants Est. completion 2023-03-31 53 sites Stand-alone
    Other conditions: Myeloid Leukemia, Chronic
    View official trial listing →
  • Withdrawn NCT NCT02923986

    Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

    Not yet reported, Not yet reported Bio-Path Holdings, Inc. Est. completion 2020-05-27 1 site Stand-alone
    Other conditions: Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Terminated NCT NCT02954523

    Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

    Not yet reported, Not yet reported Chul Kim 10 participants Est. completion 2023-03-03 2 sites Stand-alone
    Other conditions: EGFR Gene Mutation, Nonsmall Cell Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT02975115

    Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization

    Seoul St. Mary's Hospital 102 participants Est. completion 2018-01
    Other conditions: Chronic Myelocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03020030

    Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

    Not yet reported Dana-Farber Cancer Institute 560 participants Est. completion 2034-11 9 sites
    Other conditions: Acute Lymphoblastic Leukemia, Pediatric
    View official trial listing →
  • Completed NCT NCT03023046

    Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    Not yet reported University of Washington 54 participants Est. completion 2022-05-01 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
    View official trial listing →
  • Terminated NCT NCT03041701

    Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 14 participants Est. completion 2021-10-16 2 sites Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Completed NCT NCT03045120

    Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

    Bristol-Myers Squibb 118 participants Est. completion 2022-06-20 24 sites
    Other conditions: Chronic Phase Chronic Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT03079505

    Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia

    Not yet reported Hamad Medical Corporation 10 participants Est. completion 2018-09-23 1 site Stand-alone
    Other conditions: Chronic Myeloid Leukemia - Chronic Phase
    View official trial listing →
  • Active, not recruiting NCT NCT03117751

    Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

    Not yet reported, Not yet reported St. Jude Children's Research Hospital 790 participants Est. completion 2028-09-30 8 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03173612

    The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 132 participants Est. completion 2024-12 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT03193281

    KISS Study: Kinase Inhibition With Sprycel Start up

    Not yet reported University of Auckland, New Zealand 91 participants Est. completion 2025-12-31 9 sites
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT03205267

    Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients

    Not yet reported University of Bonn 127 participants Est. completion 2019-10 1 site
    Other conditions: Chronic Myelogenous Leukaemia
    View official trial listing →
  • Status unknown NCT NCT03216070

    Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

    Not yet reported Hospital Universitario Dr. Jose E. Gonzalez 12 participants Est. completion 2018-10-01 1 site Stand-alone
    Other conditions: Chronic Myelogenous Leukemia
    View official trial listing →
  • Status unknown NCT NCT03318770

    Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Gruppo Italiano Malattie EMatologiche dell'Adulto 60 participants Est. completion 2024-05 17 sites
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Status unknown NCT NCT03331211

    Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia

    Nanfang Hospital, Southern Medical University 100 participants Est. completion 2019-09-01 1 site
    Other conditions: Leukemia, Lymphoblastic, Acute
    View official trial listing →
  • Terminated NCT NCT03352427

    Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

    Not yet reported University of Michigan Rogel Cancer Center 3 participants Est. completion 2019-05-15 1 site Stand-alone
    Other conditions: Glioma, High Grade Glioma, Pontine Tumors
    View official trial listing →
  • Withdrawn NCT NCT03414450

    Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

    Not yet reported EDDC (Experimental Drug Development Centre), A*STAR Research Entities Est. completion 2023-02 6 sites Stand-alone
    Other conditions: Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Ph- Acute Lymphoblastic Leukemia (Ph-ALL), Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+), Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)
    View official trial listing →
  • Terminated NCT NCT03515200

    Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

    Not yet reported St. Jude Children's Research Hospital 12 participants Est. completion 2020-07-29 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
    View official trial listing →
  • Active, not recruiting NCT NCT03516279

    Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

    Not yet reported ECOG-ACRIN Cancer Research Group 40 participants Est. completion 2031-08-31 291 sites Stand-alone
    Other conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
    View official trial listing →
  • Withdrawn NCT NCT03560908

    Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China Est. completion 2021-12-31 1 site Stand-alone
    Other conditions: Relapsed AML, T(8;21), C-KIT Mutation
    View official trial listing →
  • Status unknown NCT NCT03564470

    Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

    Not yet reported, Not yet reported Nanfang Hospital, Southern Medical University 120 participants Est. completion 2023-08-30 1 site Stand-alone
    Other conditions: Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic, Leukemia, B-cell
    View official trial listing →
  • Status unknown NCT NCT03573596

    Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment

    Not yet reported Amsterdam UMC, location VUmc 134 participants Est. completion 2024-02-01 21 sites
    Other conditions: CML, Relapsed
    View official trial listing →
  • Active, not recruiting NCT NCT03610971

    Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 24 participants Est. completion 2026-10 8 sites Stand-alone
    Other conditions: Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase
    View official trial listing →
  • Status unknown NCT NCT03624530

    Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

    Not yet reported, Not yet reported Nanfang Hospital, Southern Medical University 82 participants Est. completion 2022-07 1 site Stand-alone
    Other conditions: Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor, Minimal Residual Disease, Allogeneic Hematopoietic Stem Cell Transplantation
    View official trial listing →
  • Completed NCT NCT03625388

    Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    Not yet reported Hikma Pharmaceuticals LLC 56 participants Est. completion 2023-07-22 5 sites
    Other conditions: Chronic Myelogenous Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03654768

    Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

    Not yet reported SWOG Cancer Research Network 81 participants Est. completion 2028-07-01 541 sites Stand-alone
    Other conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    View official trial listing →
  • Terminated NCT NCT03878524

    Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

    Not yet reported OHSU Knight Cancer Institute 2 participants Est. completion 2020-12-10 1 site Stand-alone
    Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
    View official trial listing →
  • Completed NCT NCT03880617

    Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy

    National Taiwan University Hospital 297 participants Est. completion 2020-08-07 1 site
    Other conditions: CML, GIST
    View official trial listing →
  • Completed NCT NCT03885830

    Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

    UNC Lineberger Comprehensive Cancer Center 45 participants Est. completion 2022-06-15 1 site
    Other conditions: CML, Chronic Phase, CML (Chronic Myelogenous Leukemia, CML - Philadelphia Chromosome, Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase
    View official trial listing →
  • Active, not recruiting NCT NCT03906292

    Frontline Asciminib Combination in Chronic Phase CML

    Not yet reported University of Jena 125 participants Est. completion 2027-12 21 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT03907670

    Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor

    Assiut University 45 participants Est. completion 2021-10-01
    Other conditions: Chronic Phase Chronic Myelogenous Leukemia
    View official trial listing →
  • Terminated NCT NCT04006847

    Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

    Not yet reported, Not yet reported Milton S. Hershey Medical Center 1 participants Est. completion 2021-05-21 1 site
    Other conditions: Chronic Myeloid Leukemia, Chronic Phase
    View official trial listing →
  • Completed NCT NCT04063124

    Senolytic Therapy to Modulate Progression of Alzheimer's Disease

    Not yet reported, Not yet reported The University of Texas Health Science Center at San Antonio 5 participants Est. completion 2023-01-30 1 site Stand-alone
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT04089839

    A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting

    Bristol-Myers Squibb 177 participants Est. completion 2020-01-16 1 site
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT04115059

    Dasatinib In Waldenström Macroglobulinemia

    Not yet reported Jorge J. Castillo, MD 3 participants Est. completion 2021-12-31 1 site Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia, DASATINIB
    View official trial listing →
  • Completed NCT NCT04126681

    A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

    Not yet reported Ascentage Pharma Group Inc. 144 participants Est. completion 2024-08-01 22 sites
    Other conditions: Chronic Myeloid Leukemia, Chronic Phase
    View official trial listing →
  • Status unknown NCT NCT04136015

    Early Conversion of Dasatinib in CML-CP Patients

    Nanfang Hospital, Southern Medical University 200 participants Est. completion 2021-12-31 1 site
    Other conditions: Validity and Safety
    View official trial listing →
  • Active, not recruiting NCT NCT04147533

    Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia

    Not yet reported Masaryk University 150 participants Est. completion 2026-06 8 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug
    View official trial listing →
  • Status unknown NCT NCT04150471

    Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients

    Seoul St. Mary's Hospital 79 participants Est. completion 2023-12-30 1 site
    Other conditions: Chronic Myelocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT04155411

    Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

    Not yet reported Shenzhen Second People's Hospital 65 participants Est. completion 2023-12-01 1 site Stand-alone
    Other conditions: Dasatinib, BCR-ABL, Chronic Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT04164069

    Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

    Not yet reported Anne Noonan 9 participants Est. completion 2023-06-22 1 site Stand-alone
    Other conditions: Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Esophageal Cancer, Pancreatic Cancer, Bile Duct Cancer, Gastric Cancer, Gall Bladder Cancer, Small Bowel Adenocarcinoma
    View official trial listing →
  • Terminated NCT NCT04216563

    ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

    Not yet reported M.D. Anderson Cancer Center 7 participants Est. completion 2025-03-17 1 site Stand-alone
    Other conditions: Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
    View official trial listing →
  • Status unknown NCT NCT04284202

    PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

    Not yet reported The Affiliated Hospital of Qingdao University 30 participants Est. completion 2021-12-31 1 site Stand-alone
    Other conditions: NSCLC Stage IV, ARID1A, PD-1
    View official trial listing →
  • Completed NCT NCT04313634

    Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

    Not yet reported Sundeep Khosla, M.D. 74 participants Est. completion 2023-06-06 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT04329325

    Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Not yet reported Memorial Sloan Kettering Cancer Center 17 participants Est. completion 2027-03 2 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive
    View official trial listing →
  • Withdrawn NCT NCT04439305

    Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

    Not yet reported National Cancer Institute (NCI) 1 site Stand-alone
    Other conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04530565

    Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

    Not yet reported National Cancer Institute (NCI) 348 participants Est. completion 2028-07-01 211 sites Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
    View official trial listing →
  • Status unknown NCT NCT04578847

    A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

    Not yet reported National Research Center for Hematology, Russia 100 participants Est. completion 2025-01-15 1 site Stand-alone
    Other conditions: Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT04580121

    A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

    Not yet reported Hoffmann-La Roche 59 participants Est. completion 2023-08-09 23 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04626024

    Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

    Not yet reported Baylor College of Medicine 17 participants Est. completion 2028-11-15 4 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission
    View official trial listing →
  • Status unknown NCT NCT04681820

    Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 200 participants Est. completion 2024-11 1 site
    Other conditions: CML-CP; Mutation;Suboptimal Response or Failure in TKI
    View official trial listing →
  • Active, not recruiting NCT NCT04685590

    Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

    Not yet reported Washington University School of Medicine 48 participants Est. completion 2029-01 5 sites Stand-alone
    Other conditions: Alzheimer Disease, Early Onset, Mild Cognitive Impairment
    View official trial listing →
  • Active, not recruiting NCT NCT04733534

    An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer

    Not yet reported St. Jude Children's Research Hospital 120 participants Est. completion 2027-12 1 site
    Other conditions: Frailty, Childhood Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04785300

    ALSENLITE: Senolytics for Alzheimer's Disease

    Not yet reported, Not yet reported Mayo Clinic 20 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Mild Cognitive Impairment, Alzheimer Disease
    View official trial listing →
  • Withdrawn NCT NCT04830735

    Dasatinib for the Treatment of Moderate and Severe COVID-19

    Not yet reported University of Southern California Est. completion 2024-12-15 1 site Stand-alone
    Other conditions: Symptomatic COVID-19 Infection Laboratory-Confirmed
    View official trial listing →
  • Status unknown NCT NCT04835584

    KRT-232 and TKI Study in Chronic Myeloid Leukemia

    Not yet reported, Not yet reported Kartos Therapeutics, Inc. 109 participants Est. completion 2026-06-30 26 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Withdrawn NCT NCT04845035

    Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Not yet reported University of Michigan Rogel Cancer Center Est. completion 2029-01 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04872790

    Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

    Not yet reported OHSU Knight Cancer Institute 20 participants Est. completion 2027-12-02 1 site Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
    View official trial listing →
  • Completed NCT NCT04925141

    A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

    Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 62 participants Est. completion 2019-12-06 4 sites Stand-alone
    Other conditions: Chronic Myelogenous Leukemia - Chronic Phase
    View official trial listing →
  • Completed NCT NCT04925648

    Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction

    Not yet reported St Vincent's Hospital, Sydney 4 participants Est. completion 2025-12-01 2 sites
    Other conditions: Metastatic Prostate Cancer
    View official trial listing →
  • Status unknown NCT NCT04933526

    The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients

    Not yet reported Shenzhen Second People's Hospital 118 participants Est. completion 2023-06-30 1 site
    Other conditions: Chronic Myeloid Leukemia in Chronic Phase
    View official trial listing →
  • Status unknown NCT NCT04946383

    Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

    Not yet reported TruDiagnostic 25 participants Est. completion 2022-06-30 1 site Stand-alone
    Other conditions: Aging
    View official trial listing →
  • Active, not recruiting NCT NCT04971226

    A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

    Not yet reported Novartis Pharmaceuticals 405 participants Est. completion 2031-01-18 110 sites
    Other conditions: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
    View official trial listing →
  • Status unknown NCT NCT04991532

    Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells

    Nanfang Hospital, Southern Medical University 324 participants Est. completion 2022-12 1 site
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Withdrawn NCT NCT04994561

    VIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional Supplements

    Not yet reported Vitality in Aging Research Group, Inc. Est. completion 2023-12 Stand-alone
    Other conditions: Aging
    View official trial listing →
  • Completed NCT NCT04996160

    Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

    Not yet reported Tanja Andrea Gruber 2 participants Est. completion 2023-10-16 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05007873

    ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

    Not yet reported M.D. Anderson Cancer Center 39 participants Est. completion 2028-10-30 1 site Stand-alone
    Other conditions: Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    View official trial listing →
  • Status unknown NCT NCT05024357

    A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL

    Not yet reported First Affiliated Hospital Xi'an Jiaotong University 80 participants Est. completion 2023-06-30 1 site Stand-alone
    Other conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia, ALL, Adult
    View official trial listing →
  • Status unknown NCT NCT05026229

    A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL

    Not yet reported First Affiliated Hospital Xi'an Jiaotong University 60 participants Est. completion 2023-06-30 1 site Stand-alone
    Other conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia, ALL, Adult
    View official trial listing →
  • Status unknown NCT NCT05042531

    Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia

    Not yet reported LanZhou University 30 participants Est. completion 2023-12-15 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05143840

    Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

    Not yet reported University of Alabama at Birmingham 100 participants Est. completion 2032-02 8 sites Stand-alone
    Other conditions: Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
    View official trial listing →
  • Active, not recruiting NCT NCT05192889

    Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

    Not yet reported, Not yet reported St. Jude Children's Research Hospital 35 participants Est. completion 2027-02 2 sites Stand-alone
    Other conditions: Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
    View official trial listing →
  • Terminated NCT NCT05198843

    Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

    Not yet reported, Not yet reported National Cancer Institute (NCI) 1 participants Est. completion 2023-12-20 1 site Stand-alone
    Other conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Inflammatory Carcinoma
    View official trial listing →
  • Completed NCT NCT05286528

    Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

    Pfizer 1484 participants Est. completion 2022-01-31 1 site
    Other conditions: Chronic Myeloid Leukaemia
    View official trial listing →
  • Completed NCT NCT05422885

    Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

    Not yet reported, Not yet reported Lewis Lipsitz 15 participants Est. completion 2024-01-24 1 site Stand-alone
    Other conditions: Aging
    View official trial listing →
  • Completed NCT NCT05433896

    Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

    Not yet reported Xspray Pharma AB 17 participants Est. completion 2020-12-19 1 site Stand-alone
    Other conditions: Pharmacokinetics, Drug Interactions
    View official trial listing →
  • Completed NCT NCT05439408

    Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions

    Not yet reported Xspray Pharma AB 110 participants Est. completion 2021-06-25 1 site Stand-alone
    Other conditions: Biological Availability
    View official trial listing →
  • Not yet recruiting NCT NCT05440747

    Treatment Free Remission (TFR) in CML Patients （CML-CP）Study

    Guangdong Provincial People's Hospital 203 participants Est. completion 2031-10-31
    Other conditions: Chronic Myeloid Leukemia, Treatment-free Remission
    View official trial listing →
  • Completed NCT NCT05506488

    Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease

    Not yet reported, Not yet reported Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 30 participants Est. completion 2026-02-26 1 site
    MASLDMASH Other conditions: Liver Fibrosis
    View official trial listing →
  • Status unknown NCT NCT05523661

    Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

    Not yet reported Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 15 participants Est. completion 2025-09-01 1 site Stand-alone
    Other conditions: Ph Positive ALL, CAR-T Cell, Dasatinib
    View official trial listing →
  • Active, not recruiting NCT NCT05527418

    Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection

    Not yet reported Eva Bonfill 24 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Recent HIV-1 Infection
    View official trial listing →
  • Status unknown NCT NCT05559008

    A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

    Not yet reported, Not yet reported Ruijin Hospital 116 participants Est. completion 2026-01-26 1 site Stand-alone
    Other conditions: Peripheral T Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT05619978

    French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients

    Novartis Pharmaceuticals 200 participants Est. completion 2021-10-29 1 site
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT05638763

    Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia

    Not yet reported Hospital Universitario Dr. Jose E. Gonzalez 15 participants Est. completion 2024-11 1 site Stand-alone
    Other conditions: Chronic Myeloid Leukemia, Chronic Phase
    View official trial listing →
  • Completed NCT NCT05640804

    A Bioequivalence Study of Dasatinib Tablet

    Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 56 participants Est. completion 2019-10-08 1 site Stand-alone
    Other conditions: Leukemia, Myelogenous, Chronic
    View official trial listing →
  • Active, not recruiting NCT NCT05724329

    Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 24 participants Est. completion 2028-08-05 1 site Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinomas
    View official trial listing →
  • Completed NCT NCT05743465

    A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

    Takeda 1769 participants Est. completion 2022-11-30 1 site
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT05780073

    Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment

    Not yet reported Fundació Institut Germans Trias i Pujol 60 participants Est. completion 2025-04-01 1 site Stand-alone
    Other conditions: HIV Infection Primary
    View official trial listing →
  • Active, not recruiting NCT NCT05838560

    Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

    Not yet reported Washington University School of Medicine 40 participants Est. completion 2027-10-01 1 site Stand-alone
    Other conditions: Schizophrenia, Treatment Resistant Depression, Aging, Premature
    View official trial listing →
  • Not yet recruiting NCT NCT05944783

    Bioequivalence Studies of Dasatinib 100 Mg

    Not yet reported Centro de Atencion e Investigacion Medica 46 participants Est. completion 2026-04-30 1 site
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Active, not recruiting NCT NCT05993949

    Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

    Not yet reported Stanford University 8 participants Est. completion 2040-06 1 site Stand-alone
    Other conditions: Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT06018467

    Senolytics to Improve Osteoporosis Therapy

    Not yet reported Odense University Hospital 120 participants Est. completion 2026-04-24 1 site Stand-alone
    Other conditions: Osteopenia, Osteoporosis, Age-related Bone Loss
    View official trial listing →
  • Suspended NCT NCT06055621

    Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

    Not yet reported Institut Paoli-Calmettes 35 participants Est. completion 2029-01 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT06145217

    An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL®

    Not yet reported Xspray Pharma AB 18 participants Est. completion 2023-08-29 1 site Stand-alone
    Other conditions: Drug-drug Interaction Study
    View official trial listing →
  • Not yet recruiting NCT NCT06175702

    Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

    PETHEMA Foundation 150 participants Est. completion 2030-12-25
    Other conditions: Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL
    View official trial listing →
  • Status unknown NCT NCT06355037

    Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

    Not yet reported Fudan University 10 participants Est. completion 2025-01-31 1 site Stand-alone
    Other conditions: Triple-negative Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06645886

    A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

    Not yet reported Kumquat Biosciences Inc. 13 participants Est. completion 2027-03 29 sites Stand-alone
    Other conditions: Hematologic Malignancies, Adult
    View official trial listing →
  • Completed NCT NCT06692803

    Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy

    Novartis Pharmaceuticals 2043 participants Est. completion 2023-11-30 1 site
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
  • Enrolling by invitation NCT NCT06773936

    Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

    Not yet reported SWOG Cancer Research Network 55 participants Est. completion 2033-07 16 sites
    Other conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia
    View official trial listing →
  • Completed NCT NCT07000734

    Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study

    Not yet reported Washington University School of Medicine 23 participants Est. completion 2026-04-30 1 site Stand-alone
    Other conditions: Aging, Cognitive Decline, Older Adults, Cardiovascular, Sedentary Behaviors, Immune Senescence, Motor Function
    View official trial listing →
  • Active, not recruiting NCT NCT07046182

    Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight

    Not yet reported Zhengzhou University 34 participants Est. completion 2028-05-26 1 site Stand-alone
    Other conditions: Angioimmunoblastic T-cell Lymphoma (AITL)
    View official trial listing →
  • Completed NCT NCT07144293

    Improving Physical Ability and Cellular Senescence Elimination in HIV

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 82 participants Est. completion 2026-08-26 24 sites Stand-alone
    Other conditions: HIV, Frailty, Prefrail, Aging Problems
    View official trial listing →
  • Completed NCT NCT07151820

    A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients

    Novartis Pharmaceuticals 2546 participants Est. completion 2024-10-22 1 site
    Other conditions: Leukemia, Chronic Myeloid
    View official trial listing →
  • Completed NCT NCT07188428

    Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment

    Novartis Pharmaceuticals 2298 participants Est. completion 2024-12-02 1 site
    Other conditions: Leukemia, Chronic Myeloid
    View official trial listing →
  • Not yet recruiting NCT NCT07270120

    Senolytics for Secondary Progressive MS

    Not yet reported Ohio State University 30 participants Est. completion 2028-01-15 1 site Stand-alone
    Other conditions: Multiple Sclerosis (MS) Secondary Progressive
    View official trial listing →
  • Not yet recruiting NCT NCT07301424

    Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

    Not yet reported University of Alberta 80 participants Est. completion 2031-12 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT07493408

    Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

    Not yet reported The University of Hong Kong 45 participants Est. completion 2037-12-31 1 site Stand-alone
    Other conditions: Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL), Haematopoietic Stem Cell Transplant, Allogeneic
    View official trial listing →
  • Not yet recruiting NCT NCT07538401

    ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)

    Not yet reported University Health Network, Toronto 45 participants Est. completion 2029-04-25
    Other conditions: Chronic Myeloid Leukemia (CML) in
    View official trial listing →
  • Not yet recruiting NCT NCT07804901

    Asciminib Frontline Risk Adapted

    Not yet reported Prof. Dr. med. Andreas Hochhaus 200 participants Est. completion 2031-06-30 1 site Stand-alone
    Other conditions: Chronic Myeloid Leukemia (CML)
    View official trial listing →
  • Not yet recruiting NCT NCT07839988

    De-escalation Strategy of Tyrosine Kinase Inhibitors Before Treatment Discontinuation in Patients With Chronic Myeloid Leukemia

    Not yet reported Nanfang Hospital, Southern Medical University 280 participants Est. completion 2030-12-31 1 site Stand-alone
    Other conditions: Chronic Myeloid Leukemia in Chronic Phase
    View official trial listing →
  • Not yet recruiting NCT NCT07885293

    A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 408 participants Est. completion 2033-06 1 site
    Other conditions: Chronic Myeloid Leukemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Dasatinib, Dasatinib 100 Mg Oral Tablet, Sprycel

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.